Full text
14,054 characters
· extracted from
oa-pdf
· click to expand
3131
ONCOSTREAMS: NOVEL DYNAMICS PATHOLOGICAL
MULTICELLULAR STRUCTURES INVOLVED IN
GLIOBLATOMA GROWTH AND INVASION
Andrea Comba1, Patrick Dunn, Anna E Argento, Padma Kadiyala,
Sebastien Motsch, Phillip Kish, Alon Kahana, Daniel Zamler,
Karin Muraszko, Maria G Castro and Pedro R Lowenstein
1University of Michigan
OBJECTIVES/SPECIFIC AIMS: Oncostreams represent a novel
growth pattern of GBM. In this study we uncovered the cellular
and molecular mechanism that regulates the oncostreams function
in GBM growth and invasion. METHODS/STUDY POPULATION:
We studied oncostreams organization and function using genetically
engineered mouse gliomas models (GEMM), mouse primary patient
derived GBM model and human glioma biopsies. We evaluated
the molecular landscape of oncostreams by laser capture microdis-
section (LCM) followed by RNA-Sequencing and bioinformatics
analysis. RESULTS/ANTICIPATED RESULTS: Oncostreams are
multicellular structures of 10-20 cells wide and 2-400 μm long.
They are distributed throughout the tumors in mouse and human
GBM. Oncostreams are heterogeneous structures positive for GFAP,
Nestin, Olig2 and Iba1 cells and negative for Neurofilament. Using
GEMM we found a negative correlation between oncostream density
and animal survival. Moreover, examination of patient ’s glioma
biopsies evidenced that oncostreams are present in high grade but
no in low grade gliomas. This suggests that oncostreams may play
a role in tumor malignancy. Our data also indicated that onco-
streams aid local invasion of normal brain. Transcriptome analysis
of oncostreams revealed 43 differentially expressed (DE) genes.
Functional enrichment analysis of DE genes showed that “collagen
catabolic processes ”, “positive regulation of cell migration ”, and
“extracellular matrix organization ” were the most over-represented
GO biological process. Network analysis indicated that Col1a1,
ACTA2, MMP9 and MMP10 are primary target genes. These genes
were also overexpressed in more malignant tumors (WT-IDH) com-
pared to the less malignant (IDH1- R132H) tumors. Confocal time
lapse imagining of 3D tumor slices demonstrated that oncostreams
display a collective motion pattern within gliomas that has not been
seen before. DISCUSSION/SIGNIFICANCE OF IMPACT: In sum-
mary, oncostreams are anatomically and molecularly distinctive,
regulate glioma growth and invasion, display collective motion
and are regulated by the extracellular matrix. We propose onco-
streams as novel pathological markers valuable for diagnosis, prog-
nosis and designing therapeutics for GBM patients.
3024
Osteocyte-derived CXCL12 is Essential for Load-Induced
Bone Formation in Adult Mice
Pamela Cabahug Zuckerman 1, Chao Liu, Emily Fang and
Alesha B Castillo
1New York University - H þH Clinical and Translational Science
Institute
OBJECTIVES/SPECIFIC AIMS: Our aim is to test whether osteo-
cyte-specific CXCL12 expression is critical to exercise-driven bone
formation. METHODS/STUDY POPULATION: All procedures
were approved by the NEW YORK UNIVERSITY Institutional
Animal Care and Use Committee. We generated male and female
mice in which CXCL12 was deleted from OCYs (CXCL12 Δ OCY)
by crossing CXCL12 floxed mice and 10kb DMP1-Cre transgenic
mice (gifts from Drs. Geoffrey Gurtner and Lynda Bonewald,
respectively). The 10kb DMP1-Cre has been shown to be robustly
expressed in odontoblasts and OCYs, with little to no activity in cells
from non-mineralized tissues (Luþ J Dent Res 2007). Growing male
and female mice (n=3-8/group) were given fluorochrome labels
every two weeks between 4-16 weeks of age, to monitor the role of
CXCL12 during development. A second group, of adult 16-week-old
mice (n=5/group), were subjected to tibial axial cyclic loading
(1200με, 2Hz, 120cycles, 3days/wk for 2 wks) (Liu þ Bone 2018).
Basal and load-induced periosteal (Ps) and endosteal (Es) mineral-
izing surface (MS/BS, %), mineral apposition (MAR, μm/day) and
bone formation rates (BFR/BS, μm3/μm2/year) were calculated
(Dempsterþ JBMR.2013) at mid-length. RESULTS/ANTICIPATED
RESULTS: No significant differences were detected in basal bone
formation during development. However, relative load-induced
Ps MAR (rMAR) was reduced by 50% in female (p=0.02) and 75%
in male (p=0.002) CXCL12 Δ OCY mice; and similarly, Ps rBFR/BS
was reduced by 50% in female (p=0.01) and 70% in male (p=0.001)
CXCL12Δ OCY mice (Figure 1). Es bone formation was not affected
by CXCL12 deletion. DISCUSSION/SIGNIFICANCE OF IMPACT:
In summary, osteocyte-specific CXCL12 expression plays a critical
role in exercise-driven periosteal new bone formation, suggesting that
CXCL12 signaling may positively regulate osteogenic differentiation
and/or mature osteoblast function. Further underlying mechanisms
are currently being explored. Thus, osteocyte-specific CXCL12 signal-
ing may be a promising target to enhance load-induced bone forma-
tion in patients with compromised ability to form new bone.
3332
Overexpression of CD44 is involved in the development of
the early endometriotic lesion in a xenograft model
Jennifer Knudtson1, Jessica McLaughlin, Marlen Tellez Santos,
Rajeshwar R Tekmal and Robert Schenken
1University of Texas Health Science Center San Antonio
OBJECTIVES/SPECIFIC AIMS: Previously, we showed decreased
development of endometriotic lesions in CD44 knockout mice com-
pared to control.(1) CD44 has 10 different variants and a standard
form. Menstrual endometrial cells (MECs) from women with endo-
metriosis have increased adhesion and also express higher levels of
CD44 variant 6 (v6) than v3, compared to MECs from women with-
out endometriosis. (2) Here, we assessed the effects of CD44 standard
(CD44s), CD44v3 and CD44v6 overexpression (OE) on immortal-
ized human endometrial epithelial (iEECs) and stroma cells (hESCs)
in vivo attachment in a nude mouse xenograft model. 1. Knudtson JF,
Tekmal RR, Santos MT, et al. Impaired Development of Early
Endometriotic Lesions in CD44 Knockout Mice. Reproductive scien-
ces (Thousand Oaks, Calif.). 2016;23(1):87-91. 2. Griffith JS, Liu YG,
Tekmal RR, Binkley PA, Holden AE, Schenken RS. Menstrual endo-
metrial cells from women with endometriosis demonstrate increased
adherence to peritoneal cells and increased expression of CD44 splice
variants. Fertility and sterility. 2010;93(6):1745-1749. METHODS/
STUDY POPULATION: Overexpression of CD44s, CD44v3 and
CD44v6 was carried out using lipofectamine and their expression
verified with qRT-PCR in iEEC and hESCs. Nude mice, 8-10 week
old, were injected with estrogen 1 week prior to injection of iEECs
and hESCs (n=7 per group). The cells were counted after transfection
and at least 300,000 iEECs and 300,000 hESCs were injected per
mouse. The transfected cells were tagged with cell tracker red (iEECs)
and green (hESCs). Forty-eight hours after injection into the
JCTS 2019 Abstract Supplement 111
https://doi.org/10.1017/cts.2019.255 Published online by Cambridge University Press
xenograft, the mice were sacrificed. The cells were counted using
fluorescent stereo microscopy (FSM). Percent attachment was calcu-
lated based on the number of cells visualized by FSM divided by the
number of transfected cells injected. Unpaired student t-test was per-
formed to analyze differences in the percent attachment of the cells.
RESULTS/ANTICIPATED RESULTS: The majority of cells were
attached to the peritoneum. There was increased attachment of
hESCs with OE of CD44v6 compared to control (p=0.03). CD44v6
OE did not change attachment of iEECs. There was no difference in
attachment in iEECs or hESCs with OE of CD44s or CD44v3.
DISCUSSION/SIGNIFICANCE OF IMPACT: Overexpression of
CD44v6 increases attachment of ESCs to PMCs in an in vivo xeno-
graft model. Menstrual endometrial cell type and CD44 variants play
a complex role in the development of the early endometriotic lesion.
3468
Predictive biomarkers of platinum-based chemotherapy
response in Puerto Rican Hispanics with high-grade
serous ovarian cancer.
Jeyshka M. Reyes-Gonzalez 1, Sharee Umpierre and
Pablo E. Vivas-Mejia
1University of Puerto Rico-Medical Sciences Campus
OBJECTIVES/SPECIFIC AIMS: High-grade serous ovarian carci-
noma (HGSOC) is the most common and malignant histological sub-
type of epithelial ovarian cancer. While the majority of HGSOC
patients initially respond to platinum-based chemotherapy, they often
present with recurrent chemoresistant disease, which is extremely
fatal. Therefore, there is an urgent need to identify predictive bio-
markers of platinum response and to develop rational, targeted thera-
pies to improve the outcome of patients with HGSOC. The objectives
of the present study are to profile and assess the clinical significance of
MYC network dysregulation in HGSOC. METHODS/STUDY
POPULATION: We will conduct a retrospective cohort study of
Puerto Rican Hispanics with HGSOC who underwent surgery fol-
lowed by platinum-based chemotherapy at clinical institutions in
Puerto Rico. Medical records, pathology reports, and cancer registries
will be reviewed to extract data on clinicopathological features, disease
recurrence, and death. For eligible patients, formalin-fixed, paraffin-
embedded (FFPE) tissue samples will be processed and analyzed by
quantitative Real Time PCR (qRT-PCR) and immunohistochemistry
(IHC). RESULTS/ANTICIPATED RESULTS: Expression levels of
MYC and MYC-related molecules are expected to correlate with clin-
icopathological features and prognosis of HGSOC. DISCUSSION/
SIGNIFICANCE OF IMPACT: The identification and validation of
clinically-relevant alterations in HGSOC, such as dysregulation of
the MYC network, will be crucial to guide therapy regimen, maximize
clinical benefit, and improve patient outcome.
3506
PRMT5 is a novel therapeutic target to enhance radiation
therapy for cancer treatment
Jake L Owens1, Elena Beketova, Samantha Tinsley, Andrew Asberry,
Xuehong Deng and Chang-Deng Hu
1Indiana University School of Medicine
OBJECTIVES/SPECIFIC AIMS: Prostate cancer is the second lead-
ing cause of cancer-related death among men in the U.S. and over
half of all prostate cancer patients receive radiation therapy (RT).
RT induces double-strand breaks (DSBs) in DNA which are lethal to
cells if not repaired. While potentially curative, 10% of low-risk patients
and 50% of high-risk patients treated with RT still experience tumor
recurrence. Thus, identification of novel therapeutic targets to enhance
RT will likely reduce prostate cancer mortality. The only clinical
approach to enhance RT is androgen deprivation therapy, which targets
androgen receptor (AR) signaling; however, its use is limited due to sys-
temic side effects. We recently reported that PRMT5 epigenetically acti-
vates AR which led us to investigate if targeting PRMT5 sensitizes
prostate cancer to RT. The goal of this project is to determine if
PRMT5 is a therapeutic target for prostate cancer radiosensitization
and analyze its mechanistic role in response to radiation. METHODS/
STUDY POPULATION: To evaluate if targeting PRMT5 may sensitize
prostate cancer cells to radiation, we performed a clonogenic assay of
irradiated cells. To determine if PRMT5 is required for repair of radi-
ation-induced DSBs, we performed foci analysis via immunocyto-
chemistry. We then used RNA-seq, qPCR, western blot, and ChIP to
evaluate a potential epigenetic role of PRMT5 in activating the expres-
sion of genes critical to DSB repair. To extend our findings, we analyzed
clinical data from around 18,000 of cancer patients encompassing 43
cancer types to assess if PRMT5 expression correlates with the expres-
sion of its putative target genes. RESULTS/ANTICIPATED RESULTS:
Targeting PRMT5 sensitizes prostate cancer cells to radiation inde-
pendently of AR status. RNA-seq analysis revealed putative PRMT5
target genes including several involved in DSB repair and G2 arrest.
Mechanistically, PRMT5 functions as a master epigenetic activator
of DNA damage response (DDR) genes: PRMT5 maintains the basal
expression of several DDR genes including BRCA1, BRCA2, and
RAD51 and is recruited upon radiation to DDR gene promoters to acti-
vate their expression via histone methylation. Targeting PRMT5
decreases expression of these genes at the protein level and hinders
repair of radiation-induced DSBs in multiple cancer and non-cancer
cell types. Clinically, PRMT5 expression positively correlates with
the expression of these DDR genes across all 43 cancer types analyzed.
DISCUSSION/SIGNIFICANCE OF IMPACT: PRMT5 acts as a
master epigenetic activator of genes involved in DDR and is critical
for cells to survive radiation treatment. Importantly, PRMT5 epigeneti-
cally activates multiple genes that encode for well-characterized core
repair proteins involved in HR (RAD51, RAD51AP1, RAD51D,
BRCA1 and BRCA2) and NHEJ (NHEJ1, Ku80, XRCC4, and
DNAPKcs), which may explain why PRMT5 is essential to repair
IR-induced DSBs in several cell lines. As PRMT5 is overexpressed in
many human cancers and its overexpression correlates with poor prog-
nosis, our findings suggest that more efficient DSB repair via PRMT5
overexpression in these cancers may confer survival advantages par-
ticularly following DNA damaging treatments. Lastly, because target-
ing DSB repair is a clinically validated therapeutic approach for cancer
treatment, our findings also suggest that PRMT5 targeting may be
explored as a monotherapy or in combination therapy with radiation
therapy or chemotherapy for cancer treatment.
3204
Renin-Angiotensin System Inhibitors Do Not Improve
Survival in Fibrillin-1 Hypomorphic Mice with Established
Aortic Aneurysm
Mary Burchett Sheppard 1, Jeff Zheying Chen, Debra L. Rateri,
Jessica J. Moorleghen, Mackenzie Weiland and Alan Daugherty
1University of Kentucky Center for Clinical and Translational
Science
OBJECTIVES/SPECIFIC AIMS: Drugs to attenuate aortic growth
are usually not initiated in patients with Marfan syndrome until
112 JCTS 2019 Abstract Supplement
https://doi.org/10.1017/cts.2019.255 Published online by Cambridge University Press
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.